Stada owner Nidda Healthcare, the investment vehicle controlled by Bain Capital Private Equity and Cinven Partners, has set a share price for the squeeze-out of Stada’s minority shareholders that it intends to conduct under German stock corporation law.
Nidda Sets Price For Stada Squeeze-Out
Bain Capital And Cinven Vehicle Set To Take Full Control
Nidda Healthcare, the investment vehicle controlled by Bain Capital and Cinven, has decided on a share price for the final squeeze-out of Stada’s remaining minority shareholders.
More from Strategy
• By
Sandoz has struck a deal worth up to $301m with Henlius giving it rights to a proposed ipilimumab biosimilar to Yervoy in countries across the world.
• By
Reflecting increased regulatory pressure and a wider drive towards the reshoring of pharmaceutical manufacturing to the US, Speranza has launched a new generics business called Lotus Therapeutics.
• By
As its need for development resources declines, Iconovo is cutting staff to save money as it moves to the commercialization stage for its portfolio of off-patent inhaled products.
• By
With the Global Generics & Biosimilars Awards 2025 taking place in Frankfurt this October, we bring you five key pieces of guidance to help ensure that your entries stand out from the competition.